Skip to Content

News & Events

Show:

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Crinetics announced that company management will participate in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference in Boston, Massachusetts, and the Leerink Annual Global Healthcare Conference in Miami, Florida.

READ MORE

Crinetics Pharmaceuticals, Inc. Corporate Update

Event Date: January 5, 2026

READ MORE

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes.

READ MORE

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents.

READ MORE

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit (“RSU”) awards to 10 new non-executive employees.

READ MORE